MarketFriction

Alkem Laboratories Ltd

NSE ALKEM · BSE 539523 · Pharmaceuticals
₹5,220.00 +1.09%
NSE close2026-10-01
52 week range5,051.00 - 5,933.50
Market cap₹62,772 Cr.
P/E27.6
IPO 2015 · +397% since Nifty 500Midcap 150Nifty PharmaNifty Healthcare Index No price band Delivery 66.6%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales3,4403,3242,9363,0323,4153,3743,1443,3714,0013,7373,6033,740
Expenses2,6932,6162,5342,4232,6622,6152,7522,6323,0802,9093,0862,974
Operating Profit747708402609753759391739921828517766
OPM %22%21%14%20%22%23%12%22%23%22%14%20%
Other Income64276120134931461491049065153
Interest302527292836283035425447
Depreciation747083807985112889495106100
Profit before tax648655367619780731396771896781423772
Tax %5%8%17%11%10%12%18%13%13%16%40%32%
Net Profit615604304550702641322668779653251521
EPS in Rs51.9049.7624.5545.6057.6052.3425.5855.5663.9953.1919.7843.49
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4,9055,6886,4017,3578,3448,86510,63411,59912,66812,96514,71215,081
Expenses4,0384,6875,3926,2376,8686,9208,5809,97710,41910,45211,70612,049
Operating Profit8661,0011,0091,1201,4761,9452,0541,6222,2492,5123,0073,032
OPM %18%18%16%15%18%22%19%14%18%19%20%20%
Other Income22711011582102230146101186494407412
Interest71455555655952107112122161178
Depreciation93101143193253275304310299357382395
Profit before tax9289659269551,2601,8421,8441,3052,0232,5272,8712,872
Tax %19%6%31%19%9%12%9%23%10%12%18%
Net Profit7529056387741,1491,6181,6801,0071,8112,2152,3512,204
EPS in Rs62.0274.6152.7763.6194.26132.57137.6382.31150.19181.11192.51180.45
Dividend Payout %20%20%25%25%27%23%25%61%27%25%28%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth12%11%8%13%
Compounded Profit Growth12%9%32%0%
Stock Price CAGR12%6%13%-3%
Return on Equity18%18%19%19%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital242424242424242424242424
Reserves2,9753,6684,4444,8405,4156,1377,3538,6149,02110,28811,96113,796
Borrowings1,3066586599989441,6161,7072,6681,3971,4181,3812,047
Other Liabilities9861,1841,4401,8031,8242,1692,4352,7633,3153,8444,3254,991
Total Liabilities5,2915,5346,5687,6648,2089,94611,51914,06913,75715,57517,69120,858
Fixed Assets1,3741,4501,7972,2842,5302,9082,7932,9022,6832,8732,8523,871
CWIP111172299381493363393339323159548282
Investments4815095534443242613333716224841,8461,869
Other Assets3,3253,4033,9184,5554,8616,4138,00010,45710,12912,06012,44514,836
Total Assets5,2915,5346,5687,6648,2089,94611,51914,06913,75715,57517,69120,858
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity3257264712667805851,2651,1111,6821,9481,9131,963
Cash from Investing Activity-235205-294-351-318-737-995-1,433120-1,011-1,288-1,682
Cash from Financing Activity-52-927-13885-37979-272380-1,761-1,145-811-503
Net Cash Flow39340082-73-25842-207-186-222
Free Cash Flow190472-163-4112532371,1167831,4531,7611,2781,476
CFO/OP101%107%73%47%92%59%86%73%121%105%96%86%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days524246626272666567656974
Inventory Days169169198221186198241262194197224239
Days Payable10110812214711910411210287129148161
Cash Conversion Cycle121103122135129167196225174132145152
Working Capital Days-521334405544483166135123123
ROCE %12%23%21%17%16%18%22%18%14%20%20%21%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters56.74%56.74%56.74%56.38%55.66%55.66%55.13%53.04%51.20%51.20%51.20%49.70%
FIIs6.03%8.49%9.11%8.69%9.02%10.14%9.40%9.11%9.47%9.97%10.15%10.42%
DIIs17.63%15.91%15.63%18.56%19.21%18.01%19.42%21.80%21.93%21.54%21.39%22.64%
Public19.58%18.86%18.51%16.37%16.12%16.19%16.05%16.05%17.39%17.30%17.25%17.25%
No. of Shareholders69,44265,18465,83069,62774,74484,03884,32679,74067,19664,53662,83562,822

Fundamentals

Market Cap₹ 62,772 Cr.
Current Price₹ 5,250
Stock P/E27.6
Book Value₹ 1,156
ROCE21.2 %
ROE18.9 %
Dividend Yield1.01 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)13%
Compounded Profit Growth (TTM)0%
Consolidated figures.
Valuation
Market capRs 62,413 Cr
Enterprise valueRs 62,727 Cr
P/E (TTM)28.93x
Price to book4.52x
Price to sales4.14x
EV / EBITDA18.21x
EV / EBIT20.57x
EV / sales4.16x
Price to cash flow31.79x
Earnings yield3.46%
Dividend yield1.02%
P/E, 3-year average29.13x
P/B, 3-year average5.06x
P/E, 5-year average30.99x
P/B, 5-year average4.94x
Profitability
Operating margin (excl. other income)20.44%
Operating margin (incl. other income)23.20%
EBITDA margin22.84%
Pre-tax margin19.04%
Net profit margin14.31%
Net margin, latest quarter13.90%
ROE17.84%
ROCE20.74%
ROA11.94%
ROE, 3-year average18.61%
ROCE, 3-year average20.37%
ROA, 3-year average12.40%
ROE, 5-year average17.50%
ROCE, 5-year average18.54%
ROA, 5-year average11.43%
ROIC (approx.)17.68%
Tax rate18.03%
Other income / net worth2.95%
Growth
Sales growth (latest year)13.48%
Profit growth (latest year)6.30%
Sales CAGR, 3 years8.25%
Sales CAGR, 5 years10.66%
Profit CAGR, 3 years32.74%
Profit CAGR, 5 years7.75%
Sales growth QoQ3.80%
Profit growth QoQ119.89%
Sales growth YoY (latest quarter)10.95%
Profit growth YoY (latest quarter)-21.72%
Per share
EPS (TTM)Rs 180.44
EPS (latest year)Rs 192.51
EPS (latest quarter)Rs 43.49
EPS, 3-year averageRs 174.61
EPS, 5-year averageRs 148.75
Book value per shareRs 1,155.87
Sales per shareRs 1,261.35
Cash flow per shareRs 164.18
Free cash flow per shareRs 123.45
Dividend per share (latest year)Rs 52.99
Dividend per share, 3-year averageRs 45.99
Dividend per share, 5-year averageRs 44.39
Dividends
Dividend payout27.53%
Dividend payout, 3-year average26.33%
Dividend payout, 5-year average32.89%
Efficiency
Asset turnover0.71x
Fixed asset turnover3.80x
Inventory turnover1.76x
Inventory days207 days
Debtor days74 days
Debtors turnover4.94x
Creditor days161 days
Cash conversion cycle152 days
Working capital days123 days
Leverage
Total debtRs 2,047 Cr
Cash and bankRs 1,733 Cr
Net debtRs 314 Cr
Debt to equity0.15x
Net debt / EBITDA0.09x
Interest coverage17.17x
Current ratio (filing 2026-03-31)2.55x
Quick ratio (filing 2026-03-31)1.86x
Trade payables (filing 2026-03-31)Rs 2,244 Cr
Owners' fund to total sources66.26%
Debt to assets9.81%
Cash flow
Cash from Operating Activity (latest year)Rs 1,963 Cr
Cash from Investing Activity (latest year)Rs -1,682 Cr
Cash from Financing Activity (latest year)Rs -503 Cr
Net Cash Flow (latest year)Rs -222 Cr
Free cash flow (latest year)Rs 1,476 Cr
FCFE (approx.: FCF + change in debt)Rs 2,142 Cr
Cash from ops / profit, 5 years0.95x
Sales to cash flow7.49x
Statement figures
Net sales (TTM)Rs 15,081 Cr
Net sales (latest year)Rs 14,712 Cr
Sales (latest quarter)Rs 3,740 Cr
Operating profit excl. other income (latest year)Rs 3,007 Cr
Operating profit (latest quarter)Rs 766 Cr
Other income (TTM)Rs 412 Cr
EBITDA (TTM)Rs 3,444 Cr
PBDT (TTM)Rs 3,266 Cr
Profit before tax (TTM)Rs 2,872 Cr
Tax (latest year)Rs 518 Cr
Net profit (TTM)Rs 2,157 Cr
Net profit (latest year)Rs 2,302 Cr
Net profit (latest quarter)Rs 520 Cr
Depreciation (TTM)Rs 395 Cr
Depreciation (latest quarter)Rs 100 Cr
Interest (TTM)Rs 178 Cr
Cost of goods sold (latest year)Rs 5,881 Cr
Total expenditure (latest year)Rs 11,706 Cr
Total income (latest year)Rs 15,119 Cr
Share capitalRs 24 Cr
ReservesRs 13,796 Cr
Shareholders' fundsRs 13,820 Cr
Total assetsRs 20,858 Cr
Net blockRs 3,871 Cr
Capital work in progressRs 282 Cr
InvestmentsRs 1,869 Cr
ReceivablesRs 2,979 Cr
InventoryRs 3,333 Cr
Other liabilitiesRs 4,991 Cr
Shares outstanding (crore)11.96
Ownership
Promoter holding49.70% (-3.34 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 28.9 is at the 50th percentile of its own 9.4-year range (median 28.9, low 21.6, high 63.2).
P/B 4.52 is at the 18th percentile (median 5.27).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodALKEMNifty 50Difference
1 week-2.0%-2.8% +0.8 pts
1 month-1.5%-6.8% +5.3 pts
3 months-6.2%-7.6% +1.5 pts
6 months-1.5%+0.4% -1.9 pts
1 year-5.2%-9.9% +4.7 pts
2 years-12.7%-13.6% +0.8 pts
3 years+44.8%+14.2% +30.6 pts
5 years+30.8%+27.9% +2.9 pts
192 mutual fund schemes hold about ₹11,034 Cr. Over three months 67 bought more and 35 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Mid Cap Fund1.61%1,746 -2%
ICICI Pru Multi Asset Allocation Fund0.94%826 -1%
SBI Large & Midcap Fund1.86%787 -2%
Nippon India Growth Mid Cap Fund1.25%656 +1%
Axis Midcap Fund1.34%462 +67%
ICICI Pru Focused Fund1.96%352 -14%
DSP Large & Mid Cap Fund1.89%347 +32%
DSP Midcap Fund1.64%344 -2%
ICICI Pru Healthcare Fund-4.87%341 -8%
HDFC Balanced Advantage Fund0.23%245 +1%
HDFC Large & Mid Cap Fund0.79%241 -1%
HDFC Multi Cap Fund1.16%240 -0%
Kotak Arbitrage Fund(M0.31%234 +159%
DSP Aggressive Hybrid Fund1.82%214 +45%
HDFC Aggressive Hybrid Fund0.96%213 +2%
DSP Flexi Cap Fund1.53%191 -0%
HDFC ELSS-Tax Saver Fund1.17%187 +13%
Sundaram Mid Cap Fund1.17%173 -4%
Nippon India Pharma Fund1.82%172 -3%
Sundaram Mid Cap Fund1.17%169 -4%
DSP ELSS Tax Saver Fund0.95%158 +100%
DSP Healthcare Fund4.08%157 +67%
Mirae Asset Healthcare Fund3.39%120 +2%
HDFC Pharma and Healthcare Fund3.06%101 -19%
SBI Balanced Advantage Fund0.23%97 +1%

Red flags

F-score 4 of 8
lookRegulator order or action Regulator order or action 2026-07-01: Alkem Laboratories Limited has informed the Exchange about Action(s) taken or orders passed
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2022-03-28Deepak Kumar SinghEmployees/Designated Employesell25,000Rs 9.02 CrMarket Sale
2022-03-07Mritunjay Kumar SinghDirectorbuy1,643Rs 0.52 CrMarket Purchase
2022-03-04Mritunjay Kumar SinghDirectorbuy3,357Rs 1.07 CrMarket Purchase
2022-02-23Dhananjay and Madhurima Singh TrusPromotersbuy1,050Rs 0.34 CrMarket Purchase
2022-02-22Dhananjay and Madhurima Singh TrusPromotersbuy2,000Rs 0.66 CrMarket Purchase
2021-12-29Deepak Kumar SinghEmployees/Designated Employesell2,000Rs 0.70 CrMarket Sale
2021-12-23Deepak Kumar SinghEmployees/Designated Employesell2,000Rs 0.69 CrMarket Sale
2021-12-22Deepak Kumar SinghEmployees/Designated Employesell5,000Rs 1.72 CrMarket Sale
2021-11-30Jayanti SinhaPromoter Groupother2,000,000Gift
2021-11-16Deepak Kumar SinghEmployees/Designated Employesell5,000Rs 1.79 CrMarket Sale
2021-10-04Satish Kumar SinghPromotersother50,267Off Market
2021-10-04Balmiki Prasad SinghDirectorother50,266Off Market
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹3,740 Cr +10.9% vs Jun 2025. Net profit ₹521 Cr -22.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-07Dividend - Rs 10 Per Share
2026-02-20Interim Dividend - Rs 43 Per Share
2025-08-08Dividend - Rs 8 Per Share
2025-02-14Interim Dividend - Rs 37 Per Share
2024-08-09Dividend - Rs 5 Per Share
2024-02-16Interim Dividend - Rs 35 Per Share
2023-08-10Dividend - Rs 10 Per Share
2023-02-17Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share
2022-08-08Dividend - Rs 4 Per Share
2022-02-10Interim Dividend - Rs 30 Per Sh
2021-08-09 Dividend - Rs 5 Per Share
2021-02-11 Interim Dividend - Rs 25 Per Share
2020-08-10 Annual General Meeting/Dividend - Rs 3 Per Share
2020-02-13 Interim Dividend - Rs 22 Per Share
2019-08-19 Annual General Meeting/Dividend - Rs 8 Per Share
2019-02-15 Interim Dividend - Rs 8 Per Share
2018-08-23 Annual General Meeting/Dividend- Rs 7 Per Share
2018-02-16 Interim Dividend - Rs 6 Per Share (Purpose Revised)
2017-08-31 Annual General Meeting/ Dividend -Rs 9/- Per Share
2016-11-23 Interim Dividend Rs 6/- Per Share
2016-03-18 Interim Dividend -Rs 9.70/- Per Share
DateTypeWhat it says
2026-09-24ResignationResignation of Director/KMP/SMP
2026-09-24CessationChange in Key Managerial Personnel Resignation of Chief Financial Officer
2026-09-23Concall / analyst meetSchedule of meet
2026-09-21Giving guarantees/indemnity/Issue of Corporate Guarantee
2026-09-16Press ReleaseA press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partia...
2026-09-15AppointmentAppointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the company w.e.f. September 15, 2026.
2026-09-08Press ReleaseA press release dated September 08, 2026, titled "Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside...
2026-08-27Shareholder meetingIntimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ( SEBI LODR Regulations ) - Ou...
2026-08-20Concall / analyst meetQ1 FY2027 - Earnings Conference Call Transcript
2026-08-17Shareholder meetingProceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting...
2026-08-14Concall / analyst meetLink of Recording
2026-08-14General UpdatesDisclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations ).
2026-08-14Investor PresentationInvestor Presentation
2026-08-14Board meeting outcomeAlkem Laboratories Limited has submitted to the Exchange, outcome of the Board Meeting held on 14th August, 2026
2026-08-06General UpdatesUpdate on US FDA Inspection at Company s manufacturing facility located at Amaliya, Daman
2026-08-03AppointmentAppointment of Senior Management Personnel
2026-07-30General UpdatesDisclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-07-29Shareholder meetingNotice of Annual General Meeting to be held on August 27, 2026
2026-07-29General UpdatesBusiness Responsibility and Sustainability Report for financial year ended 31st March, 2026.
2026-07-27Concall / analyst meetSchedule of meet
2026-07-23ResignationResignation of Dr. Jitendra Singh Huda as Other of the company w.e.f. July 23, 2026.
2026-07-17General UpdatesDisclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations )- Updat...
2026-07-16General UpdatesDisclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations ).
2026-07-15Shareholder meetingNotice of Court Convened General Meeting to be held on August 17, 2026
2026-07-01Regulatory actionAction(s) taken or orders passed
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.89
Max pain (expiry 2026-10-27)5,250
Largest call open interest at5,400
Largest put open interest at5,200
Implied volatility, at the money23.8%
Underlying at snapshot5,220.00
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-30308
2026-09-29625
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-04-07NCLATAlkem Laboratories Ltd & Ors VS Competition Commission of India & Ors
2021-02-22NCLATAlkem Laboratories Ltd & Ors VS Competition Commission of India & Ors
2021-02-05NCLATAlkem Laboratories Ltd & Ors VS Competition Commission of India & Ors
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Alkem Laboratories Ltd?

Alkem Laboratories Ltd (ALKEM) has a market capitalisation of Rs 62,772 Cr. at the 2026-10-01 close.

What is the P/E ratio of Alkem Laboratories Ltd?

Alkem Laboratories Ltd trades at a P/E of 27.6 on trailing twelve-month profit, at the 2026-10-01 close.

What were Alkem Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Alkem Laboratories Ltd sales was Rs 3,740 Cr (+10.9% vs Jun 2025) and net profit was Rs 521 Cr.

What is the 52-week high and low of Alkem Laboratories Ltd?

The 52-week high is Rs 5,933.50 and the 52-week low is Rs 5,051.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03